InvestSMART

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $50.500 0.56 (1.12%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. Global X S&P Biotech ETF (CURE, formerly ETFS S&P Biotech ETF) is an exchange traded fund that provides exposure to U.S. healthcare biotechnology companies. These companies are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$38 Global X Units on Issue - November 2024 5 Dec 2024 9:12AM $51.970 $50.500 fallen by 2.83%
$38 Global X Units on Issue - October 2024 4 Nov 2024 5:25PM $51.120 $50.500 fallen by 1.21%
$38 Global X Units on Issue - September 2024 4 Oct 2024 5:02PM $48.110 $50.500 risen by 4.97%
$38 Annual Financial Report 20 Sep 2024 2:52PM $51.150 $50.500 fallen by 1.27%
$38 PDS dated 16 September 2024 16 Sep 2024 5:11PM $51.730 $50.500 fallen by 2.38%
$38 Global X Units on Issue - August 2024 6 Sep 2024 5:17PM $49.700 $50.500 risen by 1.61%
$38 Global X Units on Issue - July 2024 7 Aug 2024 9:23AM $49.460 $50.500 risen by 2.10%
$38 Global X Units on Issue - June 2024 4 Jul 2024 4:50PM n/a $50.500 n/a
$38 Global X Final Distribution Announcement - June 2024 2 Jul 2024 5:27PM n/a $50.500 n/a
$38 Global X Updated Est. Distribution Announcement - June 2024 28 Jun 2024 9:53AM $47.010 $50.500 risen by 7.42%
$38 Global X Estimated Distribution Announcement - June 2024 24 Jun 2024 7:25PM $47.330 $50.500 risen by 6.70%
$38 Global X Units on Issue - May 2024 6 Jun 2024 9:58AM $46.760 $50.500 risen by 8%
$38 Global X Units on Issue - April 2024 3 May 2024 4:54PM $45.790 $50.500 risen by 10.29%
$38 Global X Units on Issue - March 2024 3 Apr 2024 10:29AM $48.000 $50.500 risen by 5.21%
$38 Half Year Accounts 11 Mar 2024 4:17PM $50.800 $50.500 fallen by 0.59%
$38 Global X Units on Issue - February 2024 4 Mar 2024 5:04PM $52.800 $50.500 fallen by 4.36%
$38 Global X Updated Units on Issue - January 2024 2 Feb 2024 3:59PM $46.200 $50.500 risen by 9.31%
$38 Global X Units on Issue - January 2024 2 Feb 2024 3:39PM $46.200 $50.500 risen by 9.31%
$38 Global X Units on Issue - December 2023 3 Jan 2024 10:02AM $45.500 $50.500 risen by 10.99%
$38 Global X Units on Issue - November 2023 4 Dec 2023 10:09AM $39.380 $50.500 risen by 28.24%
$38 Global X Units on Issue - October 2023 6 Nov 2023 3:55PM $37.600 $50.500 risen by 34.31%
$38 Global X Units on Issue - September 2023 3 Oct 2023 4:14PM $38.100 $50.500 risen by 32.55%
$38 CURE Annual Financial Report 21 Sep 2023 8:48AM $40.150 $50.500 risen by 25.78%
$38 Global X Units on Issue - August 2023 4 Sep 2023 9:36AM $41.890 $50.500 risen by 20.55%
$38 PDS dated 4 August 2023 9 Aug 2023 4:18PM $41.820 $50.500 risen by 20.76%

1 - 25 of 96 results

Page 1 of 4

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.